Pfizer Corporation

Neurocrine Biosciences, Inc.

Pfizer Products Inc.

Zhengyu Liu

James R McCarthy

Jeffrey Paul Whitten

John Charles Kath

Dominic P Behan

Charles Q Huang

Samit Kumar Bhattacharya

Norma Jacqueline Tom

Joel Morris

Scott William Bagley

Hengmiao Cheng

Robert Wayne Dugger

Theodore Otto Johnson, Jr

Eric David Cox

Philip E Erickson

Ted William Johnson

Jacqui Elizabeth Hoffman

Cheryl M Hayward

Thomas A Brandt

Lisa Chen Guo

William A Hada

Theodore Otto Johnson

Kevin Kun-Chin Liu

The present invention is directed to compounds of Formula (I), and to salts thereof, their synthesis, and their use as PI3-K&#x3b1; inhibitors and/or PI3-K&#x3b1;/mTOR dual inhibitors.

Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions

PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans.

Piperidine compounds useful as PPAR activators

Substituted bicyclic derivatives useful as anticancer agents

The invention relates to compounds of the formula 1

Ligand inhibitors for increasing levels of free corticotropin-releasing factor (CRF) in the brain are disclosed. Such ligand inhibitors cause release of CRF from the CRF/CRF-bind protein complex. Administration of the ligand inhibitors provide improvement in learning and memory, result in decreased food intake and/or provide treatment for diseases associated with low levels of CRF in the brain, notably Alzheimer's disease.

Compounds and methods for increasing endogenous levels of

Ligand inhibitors for increasing levels of free corticotropin-releasing factor (CRF) in the brain. Such ligand inhibitors cause release of CRF from the CRF/CRF-binding protein complex. Administration of the ligand inhibitors provide improvement in learning and memory, result in decreased food intake and/or provide treatment for diseases associated with low levels of CRF in the brain, notably Alzheimer's disease. The ligand inhibitor is represented by the formula: ##STR1##

Growing community of inventors

Carlsbad, CA, United States of America

Zhengyu Liu